Humanigen

CIK 0001293310 · formerly HGEN Nasdaq

SIC
2834 · Pharmaceutical Preparations
Type
Operating
Status
Delisted
Filer
Non-accelerated filer and smaller reporting company
Incorporated
Delaware
FY End
Dec 31

Delisted

Humanigen's stock was delisted from Nasdaq on October 12, 2023.

The business overview below summarizes the 10-K filed March 30, 2023, which predates these events.

Sources: 25-NSE (Oct 12, 2023)

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company headquartered in Short Hills, NJ, incorporated in Delaware, and listed on Nasdaq. The company develops proprietary "Humaneered" monoclonal antibodies — engineered high-affinity human antibodies converted from murine precursors — targeting inflammatory, immunological, and oncological conditions.

Core Technology Humanigen's proprietary Humaneered technology platform converts existing (typically murine) antibodies into engineered, high-affinity human antibodies. Humaneered antibodies are designed to offer high potency, slow off-rate, and a lower likelihood of inducing immune responses compared to chimeric or conventionally humanized antibodies.

Lead Product: Lenzilumab (LENZ) Lenzilumab is a Humaneered monoclonal antibody that neutralizes human GM-CSF (granulocyte-macrophage colony-stimulating factor), a cytokine linked to monocyte overproduction and inflammatory pathology. Humanigen is pursuing lenzilumab across three indications:

  1. Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer with ~1,700 new US/UK/Australia cases annually and a 20-month median overall survival. In a Mayo Clinic Phase 1 study, 3 of 6 patients...
Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Mar 30, 2023 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Annual results · 10-K

Fiscal 2022
Revenue
$2.5M
Net loss
-$70.7M

As reported in the fiscal 2022 annual report.

Federal lobbying · LD-2

$50.0K reported spend, four quarters through Q2 2022

Securities

Securities issued by this company
CUSIP Security Type
444863104 HGEN HUMANIGEN INC Common stock
444863203 HGENQ HUMANIGEN INC Common stock

Latest SEC filings

All filings →
Latest SEC filings by Humanigen
Form Description Filed
8-K Current Report 2024-01-08
4 Insider Transaction · Black Horse Capital Management LLC 2023-10-20
25-NSE 25-NSE 2023-10-12
8-K Current Report 2023-09-14
NT 10-Q Late 10-Q Notice 2023-08-14
8-K Current Report 2023-07-25
10-Q Quarterly Report 2023-05-15
10-K/A AMENDMENT NO. 1 2023-04-25
8-K Current Report 2023-04-19
8-K Current Report 2023-04-06
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...
Loading sponsor profile...